US healthcare spend slows on generic growth, says journal

Share this article:
The rate of growth in US healthcare spending slowed to its lowest rate since 1998 in 2007 on lethargic retail prescription drug spending and government administration, according to a Health Affairs analysis.

The journal found that US healthcare spending increased 6.1% in 2007 to $2.2 trillion, or $7,421 per person. Spending on prescription drugs grew by a mere 4.9%, while other healthcare services grew at about the same rate as or faster than in 2006.

The slowdown in spending on prescription drugs is attributable largely to increasing generic encroachment on branded drugs, driven in part by rising public spending on drugs. Spending growth from private sources accelerated in 2007 as public spending slowed, the journal found, “but public spending growth has continued to outpace private sources since 2002.”

In November, IMS Health revised its 2009 forecast for US drug spending growth down to 1%-2%, with sales between $287 billion and $297 billion.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...